Niclosamide (Synonyms: BAY2353)

Name: Niclosamide
Brand: MedChemExpress
SKU: HY-B0497
Rating: 5.0 (40 reviews)

Cat. No.: HY-B0497 Purity: 99.96%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research. Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells.

For research use only. We do not sell to patients.

CAS No. : 50-65-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 40 publication(s) in Google Scholar

Other Forms of Niclosamide:

40 Publications Citing Use of MCE Niclosamide

Cell Proliferation/Viability Assay

: Niclosamide purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114422. [Abstract]; Niclosamide (NIC; 5 μM; 24 h) significantly reduces cyclin D1 and vimentin protein expression in human endometrial cancer cells.

: Niclosamide purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114422. [Abstract]; Niclosamide (NIC; 0-8 μM; 24, 48, 72 h) significantly inhibits the metabolic viability of AN3CA, Hec1B, and Ishikawa cells both in a dose-dependent and a time-dependent manner, with the half maximal inhibitory concentration of < 1 μM at 72 h.

: Niclosamide purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114422. [Abstract]; Niclosamide (NIC) significantly suppresses the colony formation ability, and reduces the numbers, as well as diameters, of colonies formed in AN3CA, Hec1B, and Ishikawa cells.

: Niclosamide purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114422. [Abstract]; Niclosamide (NIC; 1 μM) reduces number of cells that invaded across the trans-well chamber in Hec1B and Ishikawa endometrial cancer cell lines, suggesting NIC-mediated inhibition of invasive property of endometrial cancer cells.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All Isoforms

Amebae Coccidia Leishmania Mite Plasmodium Toxoplasma Trypanosoma Schistosome

View All STAT Isoform Specific Products:

View All Isoforms

STAT3 STAT5 STAT6 STAT1

View All Antibiotic Isoform Specific Products:

View All Isoforms

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

Biological Activity
Purity & Documentation
References
Customer Review

Description

Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research^[1]. Niclosamide is a STAT3 inhibitor with an IC₅₀ of 0.25 μM in HeLa cells^[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells^[2]^[3]^[5].

IC₅₀ & Target

STAT3

0.25 μM (IC₅₀, in HeLa cells)

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	8.8 3 Compound: 5	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 24900231]
A-431	IC₅₀	8.8 3 Compound: 5	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 24900231]
A-431	IC₅₀	8.8 3 Compound: 5	Antiproliferative activity against human A431 cells after 72 hrs by MTT assay Antiproliferative activity against human A431 cells after 72 hrs by MTT assay	[PMID: 24900231]
A549	CC₅₀	22.9 3 Compound: 6	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 32045239]
A549	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human A549 cells after 120 hrs by MTT assay Antiproliferative activity against human A549 cells after 120 hrs by MTT assay	[PMID: 16680159]
A549	CC₅₀	22.9 3 Compound: 6	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 32045239]
A549	CC₅₀	22.9 3 Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay	[PMID: 33112138]
A549	CC₅₀	22.9 3 Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay	[PMID: 33112138]
A549	CC₅₀	22.9 3 Compound: 1	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by alamarBlue assay	[PMID: 33112138]
A549	CC₅₀	22.9 3 Compound: 6	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by alamar blue assay	[PMID: 32045239]
A549	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human A549 cells after 120 hrs by MTT assay Antiproliferative activity against human A549 cells after 120 hrs by MTT assay	[PMID: 16680159]
A549	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human A549 cells after 120 hrs by MTT assay Antiproliferative activity against human A549 cells after 120 hrs by MTT assay	[PMID: 16680159]
A549	IC₅₀	3 3 Compound: 5	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24900231]
A549	IC₅₀	3 3 Compound: 5	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24900231]
ASPC1	IC₅₀	1.47 3 Compound: 1	Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay	[PMID: 23459613]
ASPC1	IC₅₀	1.47 3 Compound: 1	Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay	[PMID: 23459613]
A549	IC₅₀	3 3 Compound: 5	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay Antiproliferative activity against human A549 cells after 72 hrs by MTT assay	[PMID: 24900231]
ASPC1	IC₅₀	1.47 3 Compound: 1	Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay Cytotoxicity against human AsPC1 cells after 72 hrs by MTS assay	[PMID: 23459613]
ASPC1	IC₅₀	1.47 3 Compound: Niclosamide	CYtotoxicity against human AsPC1 cells by MTS assay CYtotoxicity against human AsPC1 cells by MTS assay	[PMID: 23416191]
ASPC1	IC₅₀	1.47 3 Compound: Niclosamide	CYtotoxicity against human AsPC1 cells by MTS assay CYtotoxicity against human AsPC1 cells by MTS assay	[PMID: 23416191]
ASPC1	IC₅₀	1.47 3 Compound: Niclosamide	CYtotoxicity against human AsPC1 cells by MTS assay CYtotoxicity against human AsPC1 cells by MTS assay	[PMID: 23416191]
BHK-21	CC₅₀	> 20 3 Compound: 104	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
BHK-21	CC₅₀	>20 3 Compound: 104	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
Bone marrow cell	IC₅₀	>10 3 Compound: 89	Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
Bone marrow cell	IC₅₀	> 10 3 Compound: 89	Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
BHK-21	CC₅₀	> 20 3 Compound: 104	Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against BHK21 cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human breast cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human breast cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Bone marrow cell	IC₅₀	> 10 3 Compound: 89	Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human bone marrow cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human colon cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human colon cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
CWR22R	IC₅₀	1.61 3 Compound: 1	Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human lung cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human lung cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
CWR22R	IC₅₀	1.61 3 Compound: 1	Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
DLD-1	IC₅₀	2.39 3 Compound: Niclosamide	Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human prostate cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human prostate cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
DU-145	IC₅₀	3.65 3 Compound: 1	Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human ovarian cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human ovarian cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
DU-145	IC₅₀	0.7 3 Compound: 5	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 24900231]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human breast cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human breast cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human blood cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
HCT-116	EC₅₀	0.056 3 Compound: 1	Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay	[PMID: 28233680]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human colon cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human colon cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
HCT-116	IC₅₀	0.41 3 Compound: Niclosamide	Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human pancreatic cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human pancreatic cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human lung cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human lung cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
HCT-116	IC₅₀	0.45 3 Compound: Niclosamide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 33774344]
CWR22R	IC₅₀	1.61 3 Compound: 1	Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-positive 22Rv1 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human ovarian cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human ovarian cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
DLD-1	IC₅₀	2.39 3 Compound: Niclosamide	Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
HCT-116	IC₅₀	0.45 3 Compound: 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 26272032]
HCT-116	IC₅₀	0.25 3 Compound: 1	Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay	[PMID: 28233680]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human pancreatic cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human pancreatic cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
DU-145	IC₅₀	0.7 3 Compound: 5	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 24900231]
HEK293	IC₅₀	1.53 3 Compound: 89	Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz	[PMID: 31253529]
DU-145	IC₅₀	0.7 3 Compound: 5	Growth inhibition of human DU145 cells assessed as inhibition of colony formation after 11 to 12 days by crystal violet staining based microscopic analysis Growth inhibition of human DU145 cells assessed as inhibition of colony formation after 11 to 12 days by crystal violet staining based microscopic analysis	[PMID: 24900231]
Cancer cell lines	IC₅₀	0.13 3 Compound: 1	Cytotoxicity against human prostate cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay Cytotoxicity against human prostate cancer cells assessed as growth inhibition after 72 hrs by Cell Titer Glo Assay	[PMID: 26272032]
DU-145	IC₅₀	3.65 3 Compound: 1	Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
HEK293	IC₅₀	0.34 3 Compound: 1	Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs	[PMID: 26272032]
DLD-1	IC₅₀	2.39 3 Compound: Niclosamide	Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human DLD1 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
HCT-116	EC₅₀	0.056 3 Compound: 1	Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay	[PMID: 28233680]
HEK293	IC₅₀	0.4 3 Compound: Niclosamide	Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay	[PMID: 23453073]
HCT-116	IC₅₀	0.25 3 Compound: 1	Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay	[PMID: 28233680]
HEK293	IC₅₀	0.34 3 Compound: 1	Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay	[PMID: 30551901]
HCT-116	IC₅₀	0.41 3 Compound: Niclosamide	Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
HeLa	IC₅₀	1.4 3 Compound: 5	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24900231]
HeLa	IC₅₀	0.25 3 Compound: 5	Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay	[PMID: 24900231]
HCT-116	IC₅₀	0.45 3 Compound: 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 26272032]
HCT-116	IC₅₀	0.45 3 Compound: Niclosamide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 33774344]
HepG2 2.2.15	CC₅₀	>100 3 Compound: Niclosamide	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay	[PMID: 21553812]
HL-60	IC₅₀	0.3 3 Compound: 89	Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
HEK293	IC₅₀	0.34 3 Compound: 1	Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay	[PMID: 30551901]
HEK293	IC₅₀	0.34 3 Compound: 1	Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs	[PMID: 26272032]
HT-29	IC₅₀	0.13 3 Compound: Niclosamide	Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
HEK293	IC₅₀	0.4 3 Compound: Niclosamide	Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay	[PMID: 23453073]
HT-29	IC₅₀	7.2 3 Compound: 5	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 24900231]
HEK293	IC₅₀	1.53 3 Compound: 89	Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz	[PMID: 31253529]
HeLa	IC₅₀	0.25 3 Compound: 5	Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay	[PMID: 24900231]
Jurkat	IC₅₀	0.4 3 Compound: 89	Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
KG-1	IC₅₀	0.36 3 Compound: 89	Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
HeLa	IC₅₀	1.4 3 Compound: 5	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24900231]
HepG2 2.2.15	CC₅₀	> 100 3 Compound: Niclosamide	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay	[PMID: 21553812]
LN-229	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
LNCaP	IC₅₀	0.8 3 Compound: 1	Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
HL-60	IC₅₀	0.3 3 Compound: 89	Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
LoVo	IC₅₀	0.7 3 Compound: Niclosamide	Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay	[PMID: 16680159]
HT-29	IC₅₀	0.13 3 Compound: Niclosamide	Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
HT-29	IC₅₀	7.2 3 Compound: 5	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 24900231]
MCF7	IC₅₀	8.13 3 Compound: 1	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35334447]
MCF7	IC₅₀	1.06 3 Compound: Niclosamide	CYtotoxicity against ER-positive human MCF7 cells by MTS assay CYtotoxicity against ER-positive human MCF7 cells by MTS assay	[PMID: 23416191]
Jurkat	IC₅₀	0.4 3 Compound: 89	Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
KG-1	IC₅₀	0.36 3 Compound: 89	Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
MCF7	IC₅₀	1.06 3 Compound: 1	Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay	[PMID: 23459613]
LN-229	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
MDA-MB-231	IC₅₀	0.625 3 Compound: 27	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	1.78 3 Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35334447]
LNCaP	IC₅₀	0.8 3 Compound: 1	Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
MDA-MB-231	IC₅₀	0.8 3 Compound: Niclosamide	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 33774344]
LoVo	IC₅₀	0.7 3 Compound: Niclosamide	Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay	[PMID: 16680159]
MCF7	IC₅₀	1.06 3 Compound: 1	Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay	[PMID: 23459613]
MDA-MB-231	IC₅₀	0.79 3 Compound: Niclosamide	CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay	[PMID: 23416191]
MCF7	IC₅₀	1.06 3 Compound: Niclosamide	CYtotoxicity against ER-positive human MCF7 cells by MTS assay CYtotoxicity against ER-positive human MCF7 cells by MTS assay	[PMID: 23416191]
MDA-MB-231	IC₅₀	0.79 3 Compound: 1	Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 23459613]
DU-145	IC₅₀	0.7 3 Compound: 5	Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay	[PMID: 24900231]
DU-145	IC₅₀	0.7 3 Compound: 5	Growth inhibition of human DU145 cells assessed as inhibition of colony formation after 11 to 12 days by crystal violet staining based microscopic analysis Growth inhibition of human DU145 cells assessed as inhibition of colony formation after 11 to 12 days by crystal violet staining based microscopic analysis	[PMID: 24900231]
MCF7	IC₅₀	8.13 3 Compound: 1	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35334447]
MIA PaCa-2	IC₅₀	1.1 3 Compound: Niclosamide	Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay	[PMID: 16680159]
DU-145	IC₅₀	3.65 3 Compound: 1	Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-negative DU-145 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
NALM-6	IC₅₀	0.62 3 Compound: 89	Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
MDA-MB-231	IC₅₀	0.625 3 Compound: 27	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
PANC-1	IC₅₀	1.73 3 Compound: 1	Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay	[PMID: 23459613]
MDA-MB-231	IC₅₀	0.79 3 Compound: 1	Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 23459613]
MDA-MB-231	IC₅₀	0.79 3 Compound: Niclosamide	CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay	[PMID: 23416191]
PANC-1	IC₅₀	1.73 3 Compound: Niclosamide	CYtotoxicity against human PANC1 cells by MTS assay CYtotoxicity against human PANC1 cells by MTS assay	[PMID: 23416191]
HCT-116	EC₅₀	0.056 3 Compound: 1	Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay	[PMID: 28233680]
PC-3	IC₅₀	1.92 3 Compound: 1	Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
MDA-MB-231	IC₅₀	0.8 3 Compound: Niclosamide	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 33774344]
PC-3	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay	[PMID: 16680159]
MDA-MB-231	IC₅₀	1.78 3 Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35334447]
HCT-116	IC₅₀	0.25 3 Compound: 1	Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay Effect on ATP homeostasis in human HCT116 cells assessed as reduction in ATP level after 3 hrs in absence of glucose by ATP bioluminescent assay	[PMID: 28233680]
PC-3	IC₅₀	11.7 3 Compound: 5	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24900231]
MIA PaCa-2	IC₅₀	1.1 3 Compound: Niclosamide	Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay	[PMID: 16680159]
HCT-116	IC₅₀	0.32 3 Compound: 53	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB method Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB method	[PMID: 38142509]
SH-SY5Y	IC₅₀	0.87 3 Compound: Niclosamide	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
HCT-116	IC₅₀	0.41 3 Compound: Niclosamide	Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
NALM-6	IC₅₀	0.62 3 Compound: 89	Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
PANC-1	IC₅₀	1.73 3 Compound: 1	Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay	[PMID: 23459613]
SK-N-AS	IC₅₀	2.33 3 Compound: Niclosamide	Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
HCT-116	IC₅₀	0.45 3 Compound: 1	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 26272032]
PANC-1	IC₅₀	1.73 3 Compound: Niclosamide	CYtotoxicity against human PANC1 cells by MTS assay CYtotoxicity against human PANC1 cells by MTS assay	[PMID: 23416191]
HCT-116	IC₅₀	0.45 3 Compound: Niclosamide	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 33774344]
SW480	IC₅₀	1 3 Compound: 93	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay	[PMID: 33445154]
PC-3	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay	[PMID: 16680159]
HEK293	IC₅₀	0.34 3 Compound: 1	Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs Inhibition of Wnt/beta-catenin in HEK293 cells assessed as inhibition of Wnt3A-stimulated TOPFlash activity after 8 hrs	[PMID: 26272032]
SW480	IC₅₀	0.98 3 Compound: Niclosamide	Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
PC-3	IC₅₀	1.92 3 Compound: 1	Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
PC-3	IC₅₀	11.7 3 Compound: 5	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24900231]
SW948	IC₅₀	0.11 3 Compound: Niclosamide	Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
HEK293	IC₅₀	0.34 3 Compound: 1	Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay Inhibition of Wnt3A-stimulated Wnt/beta-catenin pathway in HEK293 cells transfected with p8xTOPFlash, Renilla luciferase plasmid pRL-TK and pLKO.1 after 8 hrs by Dual topflash luciferase reporter gene assay	[PMID: 30551901]
HEK293	IC₅₀	0.4 3 Compound: Niclosamide	Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay Inhibition of Wnt3A/beta-casein signaling in HEK293 cells after 8 hrs by TOPflash reporter assay	[PMID: 23453073]
T98G	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay	[PMID: 30583248]
SH-SY5Y	IC₅₀	0.87 3 Compound: Niclosamide	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
HEK293	IC₅₀	1.53 3 Compound: 89	Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz Inhibition of KIX-RLucN fused CBP (unknown origin) binding to KID-RLucC fused CREB (unknown origin) transfected in human HEK293 cells preincubated with compound 30 mins before before forskolin addition and measured after 90 mins in presence of coelenteraz	[PMID: 31253529]
SK-N-AS	IC₅₀	2.33 3 Compound: Niclosamide	Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
U138-MG	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay	[PMID: 30583248]
SW480	IC₅₀	0.98 3 Compound: Niclosamide	Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
U2OS	CC₅₀	>20 3 Compound: 104	Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
SW480	IC₅₀	1 3 Compound: 93	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay	[PMID: 33445154]
U-373MG ATCC	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
SW948	IC₅₀	0.11 3 Compound: Niclosamide	Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
U-87MG ATCC	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
HL-60	IC₅₀	0.3 3 Compound: 89	Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human HL60 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
U-87MG ATCC	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay	[PMID: 16680159]
T98G	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay	[PMID: 30583248]
HT-29	IC₅₀	0.13 3 Compound: Niclosamide	Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
U138-MG	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay	[PMID: 30583248]
Vero	CC₅₀	>50 3 Compound: Niclosamide	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
HT-29	IC₅₀	4.66 3 Compound: 53	Antiproliferative activity against human HT-29 cells measured after 72 hrs by SRB method Antiproliferative activity against human HT-29 cells measured after 72 hrs by SRB method	[PMID: 38142509]
U2OS	CC₅₀	> 20 3 Compound: 104	Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
Vero	CC₅₀	3.058 3 Compound: 33	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 36565533]
HT-29	IC₅₀	7.2 3 Compound: 5	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 24900231]
Vero	CC₅₀	22.1 3 Compound: 21	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
HeLa	IC₅₀	0.25 3 Compound: 5	Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay Inhibition of STAT3 in human HeLa cells after 24 hrs by luciferase reporter gene assay	[PMID: 24900231]
U-373MG ATCC	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
HeLa	IC₅₀	1.4 3 Compound: 5	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 24900231]
Vero	EC₅₀	<0.1 3 Compound: 21	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
U-87MG ATCC	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U-87MG ATCC	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay	[PMID: 16680159]
Vero	IC₅₀	0.28 3 Compound: Niclosamide	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730
HepG2 2.2.15	CC₅₀	> 100 3 Compound: Niclosamide	Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay Cytotoxicity against human HepG2(2.2.15) cells after 24 hrs by neutral red dye uptake assay	[PMID: 21553812]
Vero	EC₅₀	< 0.1 3 Compound: 21	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
Vero C1008	CC₅₀	1.96 3 Compound: NIC	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay	[PMID: 37058956]
Vero	CC₅₀	> 50 3 Compound: Niclosamide	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero C1008	CC₅₀	1.03 3 Compound: 1	Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 35344901]
Vero C1008	CC₅₀	100 3 Compound: 1	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay	[PMID: 35344901]
Vero	IC₅₀	0.28 3 Compound: Niclosamide	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730
J774.A1	CC₅₀	42.11 3 Compound: 33	Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability by MTT assay Cytotoxicity against mouse J774A.1 cells assessed as reduction in cell viability by MTT assay	[PMID: 36565533]
Vero	CC₅₀	22.1 3 Compound: 21	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
Vero C1008	CC₅₀	>35.53 3 Compound: Niclosamide	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay	[PMID: 32563814]
Vero C1008	CC₅₀	> 35.53 3 Compound: Niclosamide	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay	[PMID: 32563814]
Vero C1008	EC₅₀	4.63 3 Compound: NIC	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication incubated for 24 hrs by IFA assay Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication incubated for 24 hrs by IFA assay	[PMID: 37058956]
Jurkat	IC₅₀	0.4 3 Compound: 89	Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human Jurkat cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
KG-1	IC₅₀	0.36 3 Compound: 89	Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human KG1 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
Vero C1008	CC₅₀	1.03 3 Compound: 1	Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 35344901]
Vero C1008	CC₅₀	100 3 Compound: 1	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay	[PMID: 35344901]
LN-229	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay Antiproliferative activity against human LN229 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
LNCaP	IC₅₀	0.8 3 Compound: 1	Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-positive LNCaP cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
LoVo	IC₅₀	0.7 3 Compound: Niclosamide	Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay Antiproliferative activity against human LoVo cells after 120 hrs by MTT assay	[PMID: 16680159]
MCF7	IC₅₀	1.06 3 Compound: 1	Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay Cytotoxicity against human ER positive MCF7 cells after 72 hrs by MTS assay	[PMID: 23459613]
MCF7	IC₅₀	1.06 3 Compound: Niclosamide	CYtotoxicity against ER-positive human MCF7 cells by MTS assay CYtotoxicity against ER-positive human MCF7 cells by MTS assay	[PMID: 23416191]
MCF7	IC₅₀	8.13 3 Compound: 1	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35334447]
MDA-MB-231	IC₅₀	0.625 3 Compound: 27	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by MTT assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	0.79 3 Compound: 1	Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay Cytotoxicity against human ER negative MDA-MB-231 cells after 72 hrs by MTS assay	[PMID: 23459613]
MDA-MB-231	IC₅₀	0.79 3 Compound: Niclosamide	CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay CYtotoxicity against ER-negative human MDA-MB-231 cells by MTS assay	[PMID: 23416191]
MDA-MB-231	IC₅₀	0.8 3 Compound: Niclosamide	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 48 hrs by MTT assay	[PMID: 33774344]
MDA-MB-231	IC₅₀	1.78 3 Compound: 1	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 35334447]
MIA PaCa-2	IC₅₀	1.1 3 Compound: Niclosamide	Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay Antiproliferative activity against human MIAPaCa2cells after 120 hrs by MTT assay	[PMID: 16680159]
NALM-6	IC₅₀	0.62 3 Compound: 89	Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay Cytotoxicity against human NALM6 cells incubated for 3 days by CellTiter-Glo luminescent assay	[PMID: 31253529]
PANC-1	IC₅₀	1.73 3 Compound: 1	Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay Cytotoxicity against human PANC1 cells after 72 hrs by MTS assay	[PMID: 23459613]
PANC-1	IC₅₀	1.73 3 Compound: Niclosamide	CYtotoxicity against human PANC1 cells by MTS assay CYtotoxicity against human PANC1 cells by MTS assay	[PMID: 23416191]
PC-3	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay Antiproliferative activity against human PC3 cells after 120 hrs by MTT assay	[PMID: 16680159]
PC-3	IC₅₀	1.92 3 Compound: 1	Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay Antiproliferative activity against human AR-negative PC-3 cells assessed as cell growth inhibition incubated for 3 days by WST-1 assay	[PMID: 35772635]
PC-3	IC₅₀	11.7 3 Compound: 5	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 24900231]
SH-SY5Y	IC₅₀	0.87 3 Compound: Niclosamide	Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SH-SY5Y cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
SK-N-AS	IC₅₀	2.33 3 Compound: Niclosamide	Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay Anticancer activity against human SK-N-AS cells assessed as reduction in cell viability incubated for 48 hrs by resazurin dye based fluorescence assay	[PMID: 36208544]
SNB-19	IC₅₀	0.12 3 Compound: 1	Antiviral activity against Zika virus infected in SNB-19 cells assessed as reduction in viral titer Antiviral activity against Zika virus infected in SNB-19 cells assessed as reduction in viral titer	[PMID: 33689873]
SW480	IC₅₀	0.98 3 Compound: Niclosamide	Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human SW480 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
SW480	IC₅₀	1 3 Compound: 93	Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay Anticancer activity against human SW480 cells assessed as reduction in cell viability incubated for 12 to 24 hrs by MTS assay	[PMID: 33445154]
SW948	IC₅₀	0.11 3 Compound: Niclosamide	Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay Antiproliferative activity against human SW948 cells after 72 hrs by colorimetric MTS assay	[PMID: 30274939]
T98G	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay Antiproliferative activity against human T98G cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U-373MG ATCC	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay Antiproliferative activity against human U373 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U-87MG ATCC	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay Antiproliferative activity against human U87 cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U-87MG ATCC	IC₅₀	0.4 3 Compound: Niclosamide	Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay Antiproliferative activity against human U87MG cells after 120 hrs by MTT assay	[PMID: 16680159]
U138-MG	IC₅₀	0.3 3 Compound: 77	Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay Antiproliferative activity against human U138MG cells after 5 days by AlamarBlue assay	[PMID: 30583248]
U2OS	CC₅₀	> 20 3 Compound: 104	Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay Cytotoxicity against human U2OS cells assessed as reduction in cell viability after 16 hrs by CCK-8 assay	[PMID: 28689975]
Vero	CC₅₀	22.1 3 Compound: 21	Cytotoxicity against Vero E6 cells by MTT assay Cytotoxicity against Vero E6 cells by MTT assay	[PMID: 17663539]
Vero	CC₅₀	3.058 3 Compound: 33	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	[PMID: 36565533]
Vero	CC₅₀	> 50 3 Compound: Niclosamide	Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr	10.1101/2020.03.20.999730
Vero	EC₅₀	< 0.1 3 Compound: 21	Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA	[PMID: 17663539]
Vero	IC₅₀	0.28 3 Compound: Niclosamide	Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr	10.1101/2020.03.20.999730
Vero C1008	CC₅₀	1.03 3 Compound: 1	Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay Cytotoxicity against African Green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay	[PMID: 35344901]
Vero C1008	CC₅₀	1.96 3 Compound: NIC	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability measured after 48 hrs by CCK-8 assay	[PMID: 37058956]
Vero C1008	CC₅₀	100 3 Compound: 1	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability preincubated for 2 hrs followed by SARS-CoV-2 addition measured after 24 hrs by CPE assay	[PMID: 35344901]
Vero C1008	CC₅₀	> 35.53 3 Compound: Niclosamide	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction of cell viability measured after 48 hrs by CCK-8 assay	[PMID: 32563814]
Vero C1008	EC₅₀	4.63 3 Compound: NIC	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication incubated for 24 hrs by IFA assay Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as inhibition of viral replication incubated for 24 hrs by IFA assay	[PMID: 37058956]

In Vitro

Niclosamide (0.6 nM-46 μM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells^[3].
Niclosamide (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells ^[4].
Niclosamide (10 μM) treatment inhibits virus replication in Vero E6 cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:	BD140A, SW-13 and NCI-H295R cells
Concentration:	0.6 nM-46 µM
Incubation Time:
Result:	Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC₅₀ of 0.12 µM, 0.15 µM, and 0.53 µM in BD140A, SW-13, and NCI-H295R, respectively.

Cell Viability Assay^[4]

Cell Line:	Hela cells
Concentration:	0.05-5 μM
Incubation Time:	24 hours
Result:	Inhibited STAT3-mediated luciferase reporter activity with an IC₅₀ of 0.25 μM.

Cell Viability Assay^[4]

Cell Line:	Vero E6 cells^[5]
Concentration:	10 μM
Incubation Time:	2 days
Result:	Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells.

In Vivo

Niclosamide (oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks) treatment inhibits adrenocortical carcinoma tumor growth in vivo^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nu⁺/Nu⁺ mice injected with NCI-H295R cells^[3]
Dosage:	100 mg/kg, 200 mg/kg
Administration:	Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks
Result:	Showed a 60%-80% inhibition in tumor growth, as compared to the control group.

Clinical Trial

Molecular Weight

327.12

Formula

C₁₃H₈Cl₂N₂O₄

CAS No.

50-65-7

Appearance

Solid

Color

Light yellow to green yellow

SMILES

O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMF : 5 mg/mL (15.28 mM; Need ultrasonic)

DMSO : 4.55 mg/mL (13.91 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0570 mL	15.2849 mL	30.5698 mL
5 mM	0.6114 mL	3.0570 mL	6.1140 mL
10 mM	0.3057 mL	1.5285 mL	3.0570 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMF 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.5 mg/mL (1.53 mM); Suspended solution; Need ultrasonic

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 20 mg/mL (61.14 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 5% Cremophor EL 95% (20% HP-β-CD in Saline)
Solubility: 5 mg/mL (15.28 mM); Suspended solution; Need ultrasonic
Protocol 3

Add each solvent one by one: 10% Cremophor EL in PBS
Solubility: 3 mg/mL (9.17 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (279 KB) SDS (398 KB)

COA (248 KB) HNMR (275 KB) RP-HPLC (245 KB) LCMS (94 KB)

Handling Instructions (2659 KB)

References

[1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95. [Content Brief]

[2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96. [Content Brief]

[3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66. [Content Brief]

[4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9. [Content Brief]

[5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO / DMF	1 mM	3.0570 mL	15.2849 mL	30.5698 mL	76.4246 mL
	5 mM	0.6114 mL	3.0570 mL	6.1140 mL	15.2849 mL
	10 mM	0.3057 mL	1.5285 mL	3.0570 mL	7.6425 mL
DMF	15 mM	0.2038 mL	1.0190 mL	2.0380 mL	5.0950 mL

Niclosamide Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Niclosamide (Synonyms: BAY2353)

Customer Review

Other Forms of Niclosamide:

40 Publications Citing Use of MCE Niclosamide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All STAT Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Niclosamide Related Classifications

Keywords:

Your Recently Viewed Products:

Name
Email *

	Sorry, but the email address you supplied was invalid.

Niclosamide (Synonyms: BAY2353)

Customer Review

Other Forms of Niclosamide:

Niclosamide Related Antibodies

40 Publications Citing Use of MCE Niclosamide

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Parasite Isoform Specific Products:

View All STAT Isoform Specific Products:

View All Antibiotic Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Niclosamide Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Niclosamide Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report